Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
Support Care Cancer ; 29(5): 2509-2517, 2021 May.
Article in English | MEDLINE | ID: mdl-32929540

ABSTRACT

PURPOSE: Bisphosphonates reduce bone metastases in postmenopausal women with early-stage breast cancer but carry the risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). We describe risk factors for BRONJ and compare BRONJ provoked by infection or trauma with spontaneous lesions, which carry a better prognosis. METHODS: SWOG 0307 randomized women with stage I-III breast cancer to receive zoledronic acid (ZA), clodronate (CL), or ibandronate (IB) for 3 years, implemented BRONJ prevention guidelines, and collected information about dental health and development of BRONJ. All statistical tests were two-sided. RESULTS: Of 6018 women, 48 developed BRONJ. Infection was present in 21 (43.8%). Median time to BRONJ was 2.1 years for ZA, 2.0 years for IB, and 3.4 years for clodronate (p = 0.04). BRONJ was associated with bisphosphonate type (28/2231 (1.26%) for ZA, 8/2235 (0.36%) for CL, 12/1552 (0.77%) for IB), dental calculus (OR 2.03), gingivitis (OR 2.11), moderate/severe periodontal disease (OR 2.87), and periodontitis > 4 mm (OR 2.20) (p < 0.05). Of 57 lesions, BRONJ occurred spontaneously in 20 (35.1%) and was provoked by dental extraction in 20 (35.1%), periodontal disease in 14 (24.6%), denture trauma in 6 (10.5%), and dental surgery in 2 (3.5%). Spontaneous BRONJ occurred more frequently at the mylohyoid ridge. There were no differences in dental disease, infection, or bisphosphonate type between spontaneous and provoked BRONJ. CONCLUSION: ZA and worse dental health were associated with increased incidence of BRONJ, with a trend toward additive risk when combined. BRONJ incidence was lower than in similar studies, with prevention strategies likely linked to this. CLINICAL TRIAL NUMBER: NCT00127205 REGISTRATION DATE: July 2005.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Breast Neoplasms/drug therapy , Chemotherapy, Adjuvant/adverse effects , Diphosphonates/adverse effects , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Bone Density Conservation Agents/adverse effects , Female , Humans , Prognosis , Prospective Studies , Risk Factors
2.
JAMA Oncol ; 7(2): 246-254, 2021 Feb 01.
Article in English | MEDLINE | ID: mdl-33331905

ABSTRACT

IMPORTANCE: Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. OBJECTIVE: To define the cumulative incidence of ONJ at 3 years in patients receiving zoledronic acid for MBD from any malignant neoplasm. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, prospective observational cohort study (SWOG Cancer Research Network S0702) included patients with MBD with either limited or no prior exposure to BMAs and a clinical care plan that included use of zoledronic acid within 30 days of registration. Medical, dental, and patient-reported outcome forms were submitted at baseline and every 6 months. Follow-up was 3 years. Osteonecrosis of the jaw was defined using established criteria. Data were collected from January 30, 2009, to December 13, 2013, and analyzed from August 24, 2018, to August 6, 2020. INTERVENTIONS/EXPOSURES: Cancer treatments, BMAs, and dental care were administered as clinically indicated. MAIN OUTCOMES AND MEASURES: Cumulative incidence of confirmed ONJ, defined as an area of exposed bone in the maxillofacial region present for more than 8 weeks with no concurrent radiotherapy to the craniofacial region. Risk factors for ONJ were also examined. RESULTS: The SWOG S0702 trial enrolled 3491 evaluable patients (1806 women [51.7%]; median age, 63.1 [range, 2.24-93.9] years), of whom 1120 had breast cancer; 580, myeloma; 702, prostate cancer; 666, lung cancer; and 423, other neoplasm. A baseline dental examination was performed in 2263 patients (64.8%). Overall, 90 patients developed confirmed ONJ, with cumulative incidence of 0.8% (95% CI, 0.5%-1.1%) at year 1, 2.0% (95% CI, 1.5%-2.5%) at year 2, and 2.8% (95% CI, 2.3%-3.5%) at year 3; 3-year cumulative incidence was highest in patients with myeloma (4.3%; 95% CI, 2.8%-6.4%). Patients with planned zoledronic acid dosing intervals of less than 5 weeks were more likely to experience ONJ than patients with planned dosing intervals of 5 weeks or more (hazard ratio [HR], 4.65; 95% CI, 1.46-14.81; P = .009). A higher rate of ONJ was associated with fewer total number of teeth (HR, 0.51; 95% CI, 0.31-0.83; P = .006), the presence of dentures (HR, 1.83; 95% CI, 1.10-3.03; P = .02), and current smoking (HR, 2.12; 95% CI, 1.12-4.02; P = .02). CONCLUSIONS AND RELEVANCE: As the findings show, the cumulative incidence of ONJ after 3 years was 2.8% in patients receiving zoledronic acid for MBD. Cancer type, oral health, and frequency of dosing were associated with the risk of ONJ. These data provide information to guide stratification of risk for developing ONJ in patients with MBD receiving zoledronic acid.


Subject(s)
Bone Density Conservation Agents , Bone Neoplasms , Osteonecrosis , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Diphosphonates/adverse effects , Female , Humans , Imidazoles/adverse effects , Male , Middle Aged , Osteonecrosis/chemically induced , Osteonecrosis/drug therapy , Osteonecrosis/epidemiology , Prospective Studies , Zoledronic Acid/adverse effects
3.
J Natl Cancer Inst ; 112(7): 698-707, 2020 07 01.
Article in English | MEDLINE | ID: mdl-31693129

ABSTRACT

BACKGROUND: Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG/Alliance/Canadian Cancer Trials Group/ECOG-ACRIN/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer. METHODS: Patients with stage I-III breast cancer were randomly assigned to 3 years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided. RESULTS: A total of 6097 patients enrolled. Median age was 52.7 years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P = .49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P = .50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P = .93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%). CONCLUSIONS: We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.


Subject(s)
Breast Neoplasms/drug therapy , Diphosphonates/administration & dosage , Administration, Oral , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Bone Neoplasms/prevention & control , Bone Neoplasms/secondary , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Clodronic Acid/administration & dosage , Clodronic Acid/adverse effects , Diphosphonates/adverse effects , Disease-Free Survival , Female , Humans , Ibandronic Acid/administration & dosage , Ibandronic Acid/adverse effects , Infusions, Intravenous , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Survival Rate , Treatment Outcome , Zoledronic Acid/administration & dosage , Zoledronic Acid/adverse effects
4.
J Natl Cancer Inst Monogr ; 2019(53)2019 08 01.
Article in English | MEDLINE | ID: mdl-31425593

ABSTRACT

The increasing clinical indications for hematopoietic stem cell transplantation (HSCT) and improved clinical care throughout and following HSCT have led to not only long-term survival but also to an increasing incidence and prevalence of graft-versus-host disease (GVHD). Chronic GVHD (cGVHD) affects almost 50% of adult patients post-HSCT, with increasing incidence in pediatric patients as well. Oral cGVHD specifically has a reported prevalence ranging from 45% to 83% in patients who develop cGVHD and is more extensive in adult patients than in children. Oral cGVHD affects patients through clinically significant oral symptoms that may lead to significantly decreased caloric intake, oral infections, and increased health service utilization, and may thus affect overall health and survival. The most commonly used therapy for mucosal involvement of oral cGVHD is topical high-dose and ultra-high potency corticosteroids, and calcineurin inhibitors. This review of oral complications of cGVHD presents the clinical significance of oral cGVHD to HSCT survivors, our current understanding of the pathobiology of oral cGVHD and gaps in this evidence, and the global targeted interdisciplinary clinical research efforts, including the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Current challenges regarding the management of oral cGVHD and strategies to advance our scientific understanding of this clinically significant chronic oral disease are presented.


Subject(s)
Graft vs Host Disease/diagnosis , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Mouth Diseases/diagnosis , Mouth Diseases/etiology , Animals , Chronic Disease , Disease Management , Disease Susceptibility , Graft vs Host Disease/therapy , Hematopoietic Stem Cell Transplantation/methods , Humans , Mouth Diseases/therapy , Neoplasms/complications , Neoplasms/therapy , Phenotype , Severity of Illness Index , Symptom Assessment , Translational Research, Biomedical
5.
Support Care Cancer ; 26(10): 3553-3561, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29704111

ABSTRACT

PURPOSE: To assess magnitude and characteristics of changes in chemosensory function and quality of life (QOL) for patients receiving hematopoietic stem cell transplantation (HSCT). METHODS: Patients (aged 18 years and above) scheduled to undergo HSCT at the Seattle Cancer Care Alliance were tested for chemosensory function at three time points: pre-transplant (baseline), 30 ± 5 days (day 30), and 80 ± 5 days (day 80) post-HSCT. Gustatory function was assessed following procedures developed at the Monell-Jefferson Taste and Smell Clinic. Olfactory testing was conducted using the National Institute of Health Toolbox Odor Identification test. QOL was also assessed. RESULTS: Twenty-nine patients were enrolled in the study between August 2014 and March 2015. Twenty-three patients were included in the analysis, with 16 tested at all three time points (baseline, day 30, and day 80). The primary finding is decreased taste sensitivity for 0.32 M NaCl, 0.0056 M citric acid, and 0.018 M citric acid on day 30 following HSCT. Increased taste sensitivity for 0.32 M sucrose at day 30 was also observed. Taste sensitivity largely recovered by day 80. Olfactory identification scores were unchanged from baseline to day 30. QOL was reduced at day 30 but was restored to an acceptable level of functioning and symptoms by day 80. However, some areas remain impaired. CONCLUSIONS: Alterations in taste perception were confirmed in the early post-transplant period. This was largely resolved within 2.5 months. No obvious impairments were observed in olfactory function. QOL improved by day 80, though some oral symptoms lingered.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Quality of Life , Sensation Disorders/epidemiology , Sensation Disorders/etiology , Adult , Aged , Female , Humans , Male , Middle Aged , Odorants , Olfaction Disorders/epidemiology , Olfaction Disorders/etiology , Smell , Sodium Chloride , Taste , Taste Disorders/epidemiology , Taste Disorders/etiology
6.
Support Care Cancer ; 25(4): 1191-1199, 2017 04.
Article in English | MEDLINE | ID: mdl-27928641

ABSTRACT

PURPOSE: SWOG S0702 was a cohort study of patients with cancer with bone metastases due to any cancer. Using baseline data from S0702, this report characterizes the oral health and oral health-related quality of life (OHRQoL) of patients with advanced cancer. METHODS: S0702 case report forms captured dental assessment and patient-reported outcome (PRO) data. This analysis compares PRO dental discomfort with selected clinical assessments of dental health. This analysis focuses on the 2294 patients who underwent baseline dental examination prior to study registration, but also reports on the 1235 patients for whom only OHRQol data are available. Dental characteristics including the number of teeth and the presence of gingivitis and periodontal disease were examined for correlation with PRO of oral pain, interference with eating, smiling, speech, or quality of life. RESULTS: The median age of the study participants was 62. Greater than 60% of the 2294 patients with baseline dental assessments had none to mild plaque, calculus, gingivitis, or periodontal disease, suggesting that most of this cohort had good oral hygiene. However, in each of these same categories, approximately 6% had dental findings classified as severe conditions (poor oral hygiene). There was strong evidence that the presence of periodontal disease, gingivitis, and number of teeth was correlated with lower OHRQoL across multiple domains, including pain (mouth or jaw), interference with eating, smiling and speech, and overall quality of life. CONCLUSIONS: This report characterizes the oral health and OHRQoL of patients with advanced bone metastases receiving palliative therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00874211.


Subject(s)
Bone Neoplasms/metabolism , Jaw Diseases/physiopathology , Oral Health , Osteonecrosis/physiopathology , Adult , Aged , Bone Neoplasms/physiopathology , Cohort Studies , Dental Care , Female , Humans , Male , Middle Aged , Patient Reported Outcome Measures , Quality of Life , Registries
7.
Cancer Med ; 5(8): 1897-907, 2016 08.
Article in English | MEDLINE | ID: mdl-27334013

ABSTRACT

In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresses the state-of-the-science regarding mTOR inhibitor-associated stomatitis (mIAS), and delineates its clinical characteristics and management. Given the clinically impactful pain associated with mIAS, this review also specifically highlights new research focusing on the study of the molecular basis of pain. The incidence of mIAS varies widely (2-78%). As reported across multiple mTOR inhibitor clinical trials, grade 3/4 toxicity occurs in up to 9% of patients. Managing mTOR-associated oral lesions with topical oral, intralesional, and/or systemic steroids can be beneficial, in contrast to the lack of evidence supporting steroid treatment of oral mucositis caused by high-dose chemotherapy or radiation. However, steroid management is not uniformly efficacious in all patients receiving mTOR inhibitors. Furthermore, technology does not presently exist to permit clinicians to predict a priori which of their patients will develop these lesions. There thus remains a strategic need to define the pathobiology of mIAS, the molecular basis of pain, and risk prediction relative to development of the clinical lesion. This knowledge could lead to novel future interventions designed to more effectively prevent mIAS and improve pain management if clinically significant mIAS lesions develop.


Subject(s)
Antineoplastic Agents/adverse effects , Stomatitis/chemically induced , TOR Serine-Threonine Kinases/antagonists & inhibitors , Breast Neoplasms/drug therapy , Female , Humans , Incidence , Pain/chemically induced , Stomatitis/epidemiology , Stomatitis/pathology , Stomatitis/therapy
8.
Support Care Cancer ; 24(6): 2781-92, 2016 06.
Article in English | MEDLINE | ID: mdl-26984240

ABSTRACT

PURPOSE: There is a large body of evidence supporting the efficacy of low level laser therapy (LLLT), more recently termed photobiomodulation (PBM), for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved, may expand the applications for PBM in the management of other complications associated with HNC treatment. This article (part 1) describes PBM mechanisms of action, dosimetry, and safety aspects and, in doing so, provides a basis for a companion paper (part 2) which describes the potential breadth of potential applications of PBM in the management of side-effects of (chemo)radiation therapy in patients being treated for HNC and proposes PBM parameters. METHODS: This study is a narrative non-systematic review. RESULTS: We review PBM mechanisms of action and dosimetric considerations. Virtually, all conditions modulated by PBM (e.g., ulceration, inflammation, lymphedema, pain, fibrosis, neurological and muscular injury) are thought to be involved in the pathogenesis of (chemo)radiation therapy-induced complications in patients treated for HNC. The impact of PBM on tumor behavior and tumor response to treatment has been insufficiently studied. In vitro studies assessing the effect of PBM on tumor cells report conflicting results, perhaps attributable to inconsistencies of PBM power and dose. Nonetheless, the biological bases for the broad clinical activities ascribed to PBM have also been noted to be similar to those activities and pathways associated with negative tumor behaviors and impeded response to treatment. While there are no anecdotal descriptions of poor tumor outcomes in patients treated with PBM, confirming its neutrality with respect to cancer responsiveness is a critical priority. CONCLUSION: Based on its therapeutic effects, PBM may have utility in a broad range of oral, oropharyngeal, facial, and neck complications of HNC treatment. Although evidence suggests that PBM using LLLT is safe in HNC patients, more research is imperative and vigilance remains warranted to detect any potential adverse effects of PBM on cancer treatment outcomes and survival.


Subject(s)
Chemoradiotherapy/adverse effects , Drug-Related Side Effects and Adverse Reactions/therapy , Head and Neck Neoplasms/therapy , Low-Level Light Therapy , Drug-Related Side Effects and Adverse Reactions/etiology , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Humans , Low-Level Light Therapy/adverse effects , Low-Level Light Therapy/methods , Low-Level Light Therapy/standards
9.
Support Care Cancer ; 24(6): 2793-805, 2016 06.
Article in English | MEDLINE | ID: mdl-26984249

ABSTRACT

PURPOSE: There is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed. METHODS: Narrative review and presentation of PBM parameters are based on current evidence and expert opinion. RESULTS: PBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780-830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2-3 J (J/cm(2)), and no more than 6 J/cm(2) on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (<100 Hz); and route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations. CONCLUSION: PBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.


Subject(s)
Chemoradiotherapy/adverse effects , Clinical Protocols , Drug-Related Side Effects and Adverse Reactions/therapy , Head and Neck Neoplasms/therapy , Low-Level Light Therapy/methods , Drug-Related Side Effects and Adverse Reactions/etiology , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Humans
10.
Article in English | MEDLINE | ID: mdl-25864820

ABSTRACT

OBJECTIVE: The goal of this study was to detect dimensional changes in the mandibular cortical bone associated with bisphosphonate (BP) use and to correlate measurements of the cortical bone with the cumulative dose of BPs. STUDY DESIGN: Mandibular inferior cortical bone thickness (MICBT) was measured under the mental foramen on panoramic radiographs of patients with and without bisphosphonate-related osteonecrosis of the jaws (BRONJ) taking BPs and controls. RESULTS: Patients with BRONJ had the highest mean MICBT (6.81 ± 1.35 mm), compared with patients without BRONJ taking BPs (5.44 ± 1.09 mm) and controls (4.79 ± 0.85 mm) (P < .01). Mean MICBT of patients with BRONJ was significantly higher than that of patients without BRONJ taking BPs. There was a correlation between MICBT and cumulative dose of zolendronate. CONCLUSIONS: Measurement of MICBT on panoramic radiographs is a potentially useful tool for the detection of dimensional changes associated with BP therapy.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Mandible/diagnostic imaging , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Mandible/pathology , Middle Aged , Radiography, Panoramic , Surveys and Questionnaires
11.
Support Care Cancer ; 23(6): 1615-22, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25417041

ABSTRACT

BACKGROUND: The oral cavity is frequently affected in chronic graft-versus-host disease (cGVHD), with variable clinical presentations. The literature on the effective management of patients suffering from oral cGVHD is limited. OBJECTIVE: The objective of this study was to assess the clinical approaches used in the diagnosis and treatment of cGVHD in a group of health-care providers specialized in the oral care of oncology patients. The secondary objective was to assess the level of implementation of the National Institutes of Health (NIH) guidelines for cGVHD patients. METHODS: One hundred twenty questionnaires were sent to the members of the Oral Care Study Group (OCSG) of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The questionnaire included 50 questions about the responder's demographics, level of exposure to cGVHD patients, diagnostic and evaluation methods in their practice, preferred treatment strategies for mucosal and salivary gland involvement, and preventive measures. RESULTS: Twelve responders, representing 12 sites, stated that they treat oral cGVHD patients on a regular basis. This fraction of responders was confirmed by another online survey. Eleven out of the 12 providers were dentists. Seventy-five percent of the providers did not use biopsy in order to diagnose oral cGVHD. The NIH scale for the clinical assessment was used sporadically. The first-line topical treatment for oral mucosal cGVHD was predominantly steroids (91.7 %), and the second preferred treatment was tacrolimus (41.7 %). The preferred treatment for hyposalivation was pilocarpine (41.7 %). The recommended frequency of oral cancer screening varied; half of the providers suggest a follow-up every 6 months. CONCLUSIONS: The responses described the common practices for oral cGVHD in several specialized centers across the world. The choice of topical treatments was influenced by the availability of medications in the provider's country.


Subject(s)
Graft vs Host Disease/diagnosis , Graft vs Host Disease/therapy , Mouth Diseases/diagnosis , Mouth Diseases/therapy , Chronic Disease , Hospitals, Special , Humans , Middle Aged , Surveys and Questionnaires
12.
Biol Blood Marrow Transplant ; 20(7): 1048-55, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24704387

ABSTRACT

Chronic graft-versus-host disease (cGVHD) is an immune-mediated disorder and is the major long-term complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT). The oral mucosa, including the salivary glands, is affected in the majority of patients with cGVHD; however, at present there is only a limited understanding of disease pathobiology. In this study, we performed a quantitative proteomic analysis of saliva pooled from patients with and without oral cGVHD-cGVHD(+) and cGVHD(-), respectively-using isobaric tags for relative and absolute quantification labeling, followed by tandem mass spectrometry. Among 249 salivary proteins identified by tandem mass spectrometry, 82 exhibited altered expression in the oral cGVHD(+) group compared with the cGVHD(-) group. Many of the identified proteins function in innate or acquired immunity, or are associated with tissue maintenance functions, such as proteolysis or the cytoskeleton. Using ELISA immunoassays, we further confirmed that 2 of these proteins, IL-1 receptor antagonist and cystatin B, showed decreased expression in patients with active oral cGVHD (P < .003). Receiver operating curve characteristic analysis revealed that these 2 markers were able to distinguish oral cGVHD with a sensitivity of 85% and specificity of 60%, and showed slightly better discrimination in newly diagnosed patients evaluated within 12 months of allo-HSCT (sensitivity, 92%; specificity 73%). In addition to identifying novel potential salivary cGVHD biomarkers, our study demonstrates that there is coordinated regulation of protein families involved in inflammation, antimicrobial defense, and tissue protection in oral cGVHD that also may reflect changes in salivary gland function and damage to the oral mucosa.


Subject(s)
Graft vs Host Disease/metabolism , Mouth Diseases/metabolism , Proteomics/methods , Saliva/metabolism , Adult , Aged , Chronic Disease , Female , Humans , Male , Mass Spectrometry , Middle Aged , Mouth Mucosa/metabolism , Saliva/chemistry
13.
Support Care Cancer ; 21(1): 333-41, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23001179

ABSTRACT

BACKGROUND: The aim of this study was to review the available literature and define clinical practice guidelines for the use of laser and other light therapies for the prevention and treatment of oral mucositis. METHODS: A systematic review was conducted by the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guideline possible. RESULTS: A new recommendation was made for low-level laser (wavelength at 650 nm, power of 40 mW, and each square centimeter treated with the required time to a tissue energy dose of 2 J/cm(2) (2 s/point)) for the prevention of oral mucositis in adult patients receiving hematopoietic stem cell transplantation conditioned with high-dose chemotherapy, with or without total body irradiation. A new suggestion was made for low-level laser (wavelength around 632.8 nm) for the prevention of oral mucositis in patients undergoing radiotherapy, without concomitant chemotherapy, for head and neck cancer. No guideline was possible in other populations and for other light sources due to insufficient evidence. CONCLUSIONS: The increasing evidence in favor of low-level laser therapy allowed for the development of two new guidelines supporting this modality in the populations listed above. Evidence for other populations was also generally encouraging over a range of wavelengths and intensities. However, additional well-designed research is needed to evaluate the efficacy of laser and other light therapies in various cancer treatment settings.


Subject(s)
Low-Level Light Therapy/methods , Neoplasms/complications , Phototherapy/methods , Stomatitis/therapy , Evidence-Based Medicine , Humans , Infrared Rays/therapeutic use , Lasers, Gas/therapeutic use , Lasers, Semiconductor/therapeutic use , Neoplasms/drug therapy , Neoplasms/radiotherapy , Practice Guidelines as Topic , Stomatitis/etiology , Stomatitis/prevention & control , Stomatitis/radiotherapy
14.
Article in English | MEDLINE | ID: mdl-22668629

ABSTRACT

OBJECTIVES: The objective of this study was to develop a technique for detecting cortical bone dimensional changes in patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ). STUDY DESIGN: Subjects with BRONJ who had cone-beam computed tomography imaging were selected, with age- and gender-matched controls. Mandibular cortical bone measurements to detect bisphosphonate-related cortical bone changes were made inferior to mental foramen, in 3 different ways: within a fixed sized rectangle, in a rectangle varying with the cortical height, and a ratio between area and height. RESULTS: Twelve BRONJ cases and 66 controls were evaluated. The cortical bone measurements were significantly higher in cases than controls for all 3 techniques. The bone measurements were strongly associated with BRONJ case status (odds ratio 3.36-7.84). The inter-rater reliability coefficients were high for all techniques (0.71-0.90). CONCLUSIONS: Mandibular cortical bone measurement is a potentially useful tool in the detection of bone dimensional changes caused by bisphosphonates.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging , Bisphosphonate-Associated Osteonecrosis of the Jaw/pathology , Cone-Beam Computed Tomography/methods , Mandibular Diseases/diagnostic imaging , Mandibular Diseases/pathology , Aged , Analysis of Variance , Bone Density , Bone and Bones/diagnostic imaging , Bone and Bones/pathology , Case-Control Studies , Female , Humans , Male , Mandible/diagnostic imaging , Mandible/pathology , Middle Aged , Reference Values , Reproducibility of Results , Retrospective Studies , Statistics, Nonparametric
15.
Biol Blood Marrow Transplant ; 18(6): 922-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22079469

ABSTRACT

Results from two randomized trials have shown that oral beclomethasone dipropionate (BDP) is effective for treatment of acute gastrointestinal graft-versus-host disease. Here, we report results of a double-blind, randomized placebo-controlled phase II study designed to test the hypothesis that acute graft-versus-host disease could be prevented by administration of oral BDP, beginning before hematopoietic cell transplantation and continuing until day 75 after hematopoietic cell transplantation after myeloablative conditioning. Study drug (BDP or placebo) was administered as 1-mg immediate-release formulation plus 1-mg delayed-release formulation orally four times daily. According to the primary endpoint, systemic glucocorticoid treatment for graft-versus-host disease was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of 46 participants (67%) in the placebo arm. The secondary efficacy endpoints showed no statistically significant differences between the two arms. The proportion of participants who took at least 90% of the prescribed study drug during the first 4 weeks after hematopoietic cell transplantation was 54% overall. Lower severity of mucositis strongly correlated with higher adherence to the schedule of study drug administration. Inconsistent adherence related to mucositis during recovery after myeloablative conditioning may have obscured a beneficial therapeutic effect in the current study.


Subject(s)
Beclomethasone/administration & dosage , Glucocorticoids/administration & dosage , Graft vs Host Disease/prevention & control , Leukemia/therapy , Mucositis/prevention & control , Myelodysplastic Syndromes/therapy , Acute Disease , Administration, Oral , Adolescent , Adult , Antineoplastic Agents/administration & dosage , Beclomethasone/therapeutic use , Child , Double-Blind Method , Drug Administration Schedule , Female , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/immunology , Gastrointestinal Tract/physiopathology , Glucocorticoids/therapeutic use , Hematopoietic Stem Cell Transplantation , Humans , Leukemia/immunology , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Patient Compliance , Placebos , Transplantation, Homologous
16.
Tex Dent J ; 127(5): 463-81, 2010 May.
Article in English | MEDLINE | ID: mdl-20549993

ABSTRACT

Effective pain control for mucositis requires constant attention and willingness on the part of managing clinicians to evaluate and adapt pain-relieving strategies throughout the period of risk for oral mucositis. By utilizing the principles of an individualized, tiered approach to pain management that addresses the multidimensional components of a patient's pain, maximum comfort can be consistently provided while reducing the risk for side effects.


Subject(s)
Antineoplastic Agents/adverse effects , Cranial Irradiation/adverse effects , Facial Pain/drug therapy , Stomatitis/complications , Stomatitis/etiology , Analgesics, Opioid/adverse effects , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Humans , Mucositis/complications , Mucositis/etiology , Mucositis/prevention & control , Oral Hygiene , Oropharynx , Preoperative Care , Stomatitis/prevention & control
19.
Rev Recent Clin Trials ; 4(2): 99-109, 2009 May.
Article in English | MEDLINE | ID: mdl-19463106

ABSTRACT

Bisphosphonate osteonecrosis (BON) is a relatively recent adverse drug event that affects the oral cavity almost exclusively. It has been reported in individuals with metastatic breast, prostate, and lung cancer as well as in multiple myeloma. It has also been reported in a small subset of individuals who have been treated with bisphosphonate therapy for osteoporosis and Paget's disease of bone. Published studies to date have been characterized by relatively small sample sizes. Based on these studies, incidence appears to range between 0.1% and 11% depending on the population being studied and a number of other co-factors that have not been completely understood. The pathobiology of BON has not been fully elucidated and risk factors involved in the process need confirmation. Patients with this complication have altered quality of life and can suffer from discomfort and pain. Management is difficult and, while many treatment protocols have been proposed, at best they have only had partial success. This review of literature discusses a number of issues involving BON, with focus on the definition, possible association of BON and bisphosphonate therapy, pathobiology of BON and several additional research questions that need further investigation.


Subject(s)
Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Jaw Diseases/chemically induced , Osteonecrosis/chemically induced , Biomedical Research , Clinical Protocols , Humans , Jaw Diseases/therapy , Osteonecrosis/therapy
20.
Dent Clin North Am ; 52(1): 79-109, viii-ix, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18154866

ABSTRACT

Hematopoietic cell transplantation is used to treat malignancies, hematologic and immune deficiency states, marrow failure syndromes, and autoimmune diseases. Graft-versus-host disease (GVHD) is a clinical syndrome seen following allogeneic transplantation where donorderived immunocompetent T cells and inflammatory responses attack host tissues. GVHD can cause significant morbidity and even result in mortality. The oral cavity is a frequently involved site with clinical changes resembling autoimmune collagen vascular diseases. Recognition, diagnosis, and monitoring of oral GVHD can help with diagnosis and grading of GVHD and judging responses to therapy. Topical and local management of symptomatic oral GVHD can reduce oral symptoms that can interfere with oral function and quality of life, and can reduce the need for more intensive immunosuppressive systemic therapies.


Subject(s)
Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Mouth Diseases/etiology , Acute Disease , Adrenal Cortex Hormones/therapeutic use , Chronic Disease , Graft vs Host Disease/pathology , Graft vs Host Disease/therapy , Humans , Immunosuppressive Agents/therapeutic use , Mouth Diseases/pathology , Mouth Diseases/therapy , Mouth Mucosa/drug effects , Mouth Mucosa/pathology , Mouth Mucosa/radiation effects , Oral Hygiene , Salivary Gland Diseases/etiology , Salivary Gland Diseases/therapy , Taste Disorders/drug therapy , Taste Disorders/etiology
SELECTION OF CITATIONS
SEARCH DETAIL